Gossamer Bio (GOSS) Net Income towards Common Stockholders (2022 - 2025)
Historic Net Income towards Common Stockholders for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to -$48.2 million.
- Gossamer Bio's Net Income towards Common Stockholders fell 5654.64% to -$48.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.8 million, marking a year-over-year decrease of 11324.01%. This contributed to the annual value of -$56.5 million for FY2024, which is 6856.36% up from last year.
- Per Gossamer Bio's latest filing, its Net Income towards Common Stockholders stood at -$48.2 million for Q3 2025, which was down 5654.64% from -$38.3 million recorded in Q2 2025.
- Over the past 5 years, Gossamer Bio's Net Income towards Common Stockholders peaked at $49.2 million during Q2 2024, and registered a low of -$59.0 million during Q3 2022.
- Its 4-year average for Net Income towards Common Stockholders is -$39.8 million, with a median of -$44.7 million in 2024.
- Per our database at Business Quant, Gossamer Bio's Net Income towards Common Stockholders skyrocketed by 21585.09% in 2024 and then crashed by 17774.01% in 2025.
- Gossamer Bio's Net Income towards Common Stockholders (Quarter) stood at -$57.2 million in 2022, then rose by 15.85% to -$48.1 million in 2023, then surged by 31.4% to -$33.0 million in 2024, then tumbled by 46.0% to -$48.2 million in 2025.
- Its last three reported values are -$48.2 million in Q3 2025, -$38.3 million for Q2 2025, and -$39.3 million during Q1 2025.